Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase.
CAS：1357920-84-3
分子式：C33H44FN5O3
分子量：577.73
纯度：98%
存储：Store at -20°C

Background:

Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase.

TSR-011 has antitumour activity in the clinical trials.

TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models[1].

参考文献:
[1]. Sullivan I, et al. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47.